Clinical Data New data build case for Roche’s oral BTK drug for MS PharmaphorumRoche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.Clinical DataNeuroscienceRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaphorum Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns. Clinical DataNeuroscienceRead full story Post navigation Previous: Pivotal trial of Moderna’s H5N1 bird flu jab gets underwayNext: MSD-backed Ray locks in $125m to back eye drug pipeline Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
